155 related articles for article (PubMed ID: 27104669)
1. α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid.
Xia Y; Chen J; Gong C; Chen H; Sun J
Med Sci Monit; 2016 Apr; 22():1360-7. PubMed ID: 27104669
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.
Xia Y; Li Y; Westover KD; Sun J; Chen H; Zhang J; Fisher DE
PLoS One; 2016; 11(5):e0155217. PubMed ID: 27152946
[TBL] [Abstract][Full Text] [Related]
3. Altered mRNA expression related to the apoptotic effect of three xanthones on human melanoma SK-MEL-28 cell line.
Wang JJ; Zhang W; Sanderson BJ
Biomed Res Int; 2013; 2013():715603. PubMed ID: 24175297
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
Haarberg HE; Paraiso KH; Wood E; Rebecca VW; Sondak VK; Koomen JM; Smalley KS
Mol Cancer Ther; 2013 Jun; 12(6):901-12. PubMed ID: 23538902
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of cell proliferation by combined targeting with kinase inhibitors and dietary xanthone is a promising strategy for melanoma treatment.
Xia Y; Sun J
Clin Exp Dermatol; 2018 Mar; 43(2):149-157. PubMed ID: 29168273
[TBL] [Abstract][Full Text] [Related]
6. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
7. Anticancer effects of α-mangostin in OVACAR-3 human ovarian carcinoma cells are mediated via involvement of reactive oxygen species, mitochondrial -mediated apoptosis, suppression of cell migration and invasion and m-TOR/PI3K/AKT signaling pathway.
Yu Y; Fei Z; Qin L
J BUON; 2020; 25(5):2293-2300. PubMed ID: 33277848
[TBL] [Abstract][Full Text] [Related]
8. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
Emran AA; Chinna Chowdary BR; Ahmed F; Hammerlindl H; Huefner A; Haass NK; Schuehly W; Schaider H
Cancer Med; 2019 Mar; 8(3):1186-1196. PubMed ID: 30793515
[TBL] [Abstract][Full Text] [Related]
9. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
10. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
11. Alpha-mangostin induces apoptosis through activation of reactive oxygen species and ASK1/p38 signaling pathway in cervical cancer cells.
Lee CH; Ying TH; Chiou HL; Hsieh SC; Wen SH; Chou RH; Hsieh YH
Oncotarget; 2017 Jul; 8(29):47425-47439. PubMed ID: 28537893
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.
Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B
Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811
[TBL] [Abstract][Full Text] [Related]
13. Alpha-mangostin inhibits intracellular fatty acid synthase and induces apoptosis in breast cancer cells.
Li P; Tian W; Ma X
Mol Cancer; 2014 Jun; 13():138. PubMed ID: 24894151
[TBL] [Abstract][Full Text] [Related]
14. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.
Hayes TK; Luo F; Cohen O; Goodale AB; Lee Y; Pantel S; Bagul M; Piccioni F; Root DE; Garraway LA; Meyerson M; Johannessen CM
Cancer Res; 2019 May; 79(9):2352-2366. PubMed ID: 30819666
[TBL] [Abstract][Full Text] [Related]
15. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice.
Wang F; Ma H; Liu Z; Huang W; Xu X; Zhang X
Biomed Pharmacother; 2017 Aug; 92():672-680. PubMed ID: 28582759
[TBL] [Abstract][Full Text] [Related]
16. Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.
Garay T; Kenessey I; Molnár E; Juhász É; Réti A; László V; Rózsás A; Dobos J; Döme B; Berger W; Klepetko W; Tóvári J; Tímár J; Hegedűs B
PLoS One; 2015; 10(2):e0117021. PubMed ID: 25646931
[TBL] [Abstract][Full Text] [Related]
17. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.
Takashima A; English B; Chen Z; Cao J; Cui R; Williams RM; Faller DV
ACS Chem Biol; 2014 Apr; 9(4):1003-14. PubMed ID: 24506253
[TBL] [Abstract][Full Text] [Related]
19. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
20. Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas.
Hirata AS; Rezende-Teixeira P; Machado-Neto JA; Jimenez PC; Clair JJ; Fenical W; Costa-Lotufo LV
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]